Best response after combination therapy with 8 cycles of carfilzomib/lenalidomide/dexamethasone in high-risk smoldering multiple myeloma and newly diagnosed multiple myeloma: results from 2 parallel phase 2 trials
| Best treatment response . | High-risk smoldering myeloma (%) (N = 12) . | Newly diagnosed multiple myeloma (%) (N = 45) . |
|---|---|---|
| Complete response | 12 (100) | 25 (56) |
| EuroFlow (MRD 10−5 negative) | 11/12 (92) | 33/43 (77) |
| Next Gen VDJ Sequencing (MRD 10−6 negative) | 9/12 (75) | 14/33 (42) |
| Best treatment response . | High-risk smoldering myeloma (%) (N = 12) . | Newly diagnosed multiple myeloma (%) (N = 45) . |
|---|---|---|
| Complete response | 12 (100) | 25 (56) |
| EuroFlow (MRD 10−5 negative) | 11/12 (92) | 33/43 (77) |
| Next Gen VDJ Sequencing (MRD 10−6 negative) | 9/12 (75) | 14/33 (42) |
Adapted from Korde et al.14